genomic assays for chemotherapy decisions in er-positive/her2-negative breast cancer
Published 7 years ago • 841 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
1:30
utilizing genomic assays for decision making in early stage breast cancer
-
26:38
genomic assays and breast cancer
-
4:06
breast cancer: genomic testing
-
2:37
genomic testing and targeted therapy in breast cancer: 2023 review and renew lake tahoe
-
30:56
adjuvant treatment for early stage hormone positive breast cancer: role of genomic signatures
-
1:28
what role do genomic assays play in the decision to extend endocrine therapy?
-
16:07
2021 west oncology | breast cancer | genomic expression panels - esbc chemotherapy decision-making
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer
-
1:31:37
personalizing treatment decisions in her2-altered breast cancer
-
1:30
dr. brufsky on genomic assays for breast cancer
-
1:40
dr. simon on genomic assays for patients with breast cancer
-
2:33
challenges with neoadjuvant endocrine therapy in breast cancer
-
4:22
how to use endocrine therapy in premenopausal women with er metastatic breast cancer
-
7:42
breast cancer: genomic testing for adjuvant therapy
-
2:48
dr. rivera: how do you decide between hormone therapies in patients with er /pr tumors?
-
41:53
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
59:32
breast cancer 360: genomic testing and new directions for treatment
-
41:15
advocate chat: genomic profiling in breast cancer for treatment decision making
-
1:55
dr. finn on treating er breast cancer patients with antiestrogens